Allergic Rhinitis Drugs Market Forecast 2016-2026

アレルギー性鼻炎治療薬の世界市場予測2016-2026

◆タイトル:Allergic Rhinitis Drugs Market Forecast 2016-2026
◆商品コード:VGAIN61118
◆調査・発行会社:visiongain
◆発行日:2016年9月
◆ページ数:240
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,999 ⇒換算¥295,852見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、アレルギー性鼻炎治療薬の世界市場について調査・分析し、アレルギー性鼻炎治療薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
1. レポート概要

2. アレルギー性鼻炎治療薬の概要

3. アレルギー性鼻炎治療薬の世界市場2016-2026

4. 経口抗ヒスタミン薬市場:市場分析・予測2016-2026

5. 鼻腔内副腎皮質ステロイド薬市場:市場分析・予測2016-2026

6. 免疫療法およびワクチン:市場分析・予測2016-2026

7. 鼻腔内抗ヒスタミン薬市場:市場分析・予測2016-2026

8. アレルギー性鼻炎治療薬の主要国市場2016-2026

9. アレルギー性鼻炎治療薬市場における主要企業2016-2026

10. アレルギー性鼻炎治療薬:研究開発パイプライン2016-2026

11. アレルギー性鼻炎治療薬市場の定性分析2016-2026

12. 結論

What can be expected from the Allergic Rhinitis Drugs Market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.

Our 240-page report provides 173 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the all the major categories of the allergic rhinitis drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications
How will submarkets perform to 2026? Our study forecasts revenues in the following Allergic Rhinitis Drugs submarkets:
• Intranasal Anthistamines
• Intranasal Corticosteroids
• Oral Antihistamines
• Immunotherapy and Vaccines

See detailed profiles or revenue forecasts for some the leading products in the market
How will leading drugs perform to 2026? Our study provides detailed profiles or forecasts revenues for a number of drugs in the allergic rhinitis drugs market including:
• Patanase
• Astepro
• Astelin
• Dymista
• Nasonex
• Avamys
• Veramyst
• Flixonase
• Rhinocort
• Omnaris
• Nasacort
• Beconase
• Qnasl
• Zetonna
• Allegra
• Zyrtec
• Claritin
• Xyzal
• Allelock
• Clarinex
• Ebastel
• Talion
• Staloral
• Alutard SQ
• Grazax
• Ragwitek

See revenue forecasts for the leading international markets
How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets including products, including:
• US
• EU5 – Germany, UK, France, Italy and Spain
• China
• Japan
• India
• Russia
• Brazil

Leading companies and potential for market growth
Visiongain forecasts overall revenue for the Allergic Rhinitis Drugs Market will reach $16,500m in 2026. We predict a high revenue growth over the forecast period driven by an urbanisation, climate change, increasing patient expectations and a higher incidence of allergic rhinitis symptoms, rapid growth of emerging economies and emerging allergic rhinitis drug technologies.

Our work analyses the key companies in the market. See visiongain’s analysis of six leading companies, including these:
• GSK
• Merck & Co
• Sanofi
• Johnson & Johnson
• ALK-Abello
• UCB
• Kyowo Hako Kirin
• Stallergenes Greer

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Historic revenue, analysis and discussion of company performance
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the allergic rhinitis drugs industry?
Our new report discusses issues and events affecting the allergic rhinitis drugs market. You will find discussions, including qualitative analyses:
• Highly competitive market with significant variations in different geographic regions
• Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
• Future paradigm-shifting pipeline products
• Patent expirations and invalidations of major drugs
• Launches of new drug categories

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

Allergic Rhinitis Drugs Market Forecast 2016-2026: Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co.
In summary, our 240-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the Allergic Rhinitis Drugs market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2026 for each major submarket – discover prospects for leading allergic rhinitis drugs in the following areas: intranasal corticosteroids, intranasal antihistamines, oral antihistamines, and immunotherapy and vaccines.
• Detailed profiles or revenue forecasts to 2026 for 25 of the leading products in the allergic rhinitis drugs market – discover prospects for leading allergic rhinitis drugs: Patanase, Astepro, Astelin, Dymista, Nasonex, Avamys, Veramyst, Fixonase, Rhinocort, Omnaris, Nasacort, Beconase, Qnasl, Zetonna, Allegra, Zyrtec, Claritin, Xyzal, Allelock, Clarinex, Ebastel, Talion, Staloral, Alutard SQ, Grazax, Ragwitek.
• Revenue forecasts to 2026 for eleven leading national markets and one leading regional markets – US, EU5, China, Japan, India, Russia, and Brazil.
• Assessment of eight leading companies – analysis of products, revenue, mergers & acquisitions, product type and product pipelines
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

【レポートの目次】

1. Report Overview
1.1 Global Allergic Rhinitis Drugs: Market Overview
1.2 Global Allergic Rhinitis Drugs Market Segmentation
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is This Report For?
1.9 Methodology
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Visiongain Reports
1.12 About Visiongain

2. An Introduction to Allergic Rhinitis Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.1.1 Allergic Rhinitis Treatments – An Industry Overview
2.2 A Brief Overview of Allergy
2.3 Allergic Rhinitis
2.3.1 The Global Prevalence of Allergic Rhinitis
2.3.2 Pathophysiology of Allergic Rhinitis: IgEs and Mast Cells
2.3.3 Symptoms of Allergic Rhinitis
2.3.4 Classification of Allergic Rhinitis
2.3.4.1 Non-Allergic Rhinitis and Mixed Rhinitis
2.3.5 Seasonal Allergic Rhinitis (Hay Fever)
2.3.6 Perennial Allergic Rhinitis
2.3.7 Diagnosis of Allergic Rhinitis
2.4 Treatment of Allergic Rhinitis
2.4.1 Antihistamines
2.4.1.1 First-Generation Antihistamines
2.4.1.2 Second- And Third-Generation Antihistamines
2.4.2 Corticosteroids
2.4.2.1 First-, Second- And Third-Generation Intranasal Corticosteroids
2.4.2.2 Combination Drug Products
2.4.3 Leukotriene Receptor Antagonists
2.4.4 Cromolyn (cromoglicic acid)
2.4.5 Decongestants
2.4.6 Saline Nasal Sprays
2.4.7 Immunotherapy and Vaccines
2.5 Phases of Clinical Trials
2.6 Scope of this Report

3. The Global Allergic Rhinitis Drugs Market, 2016-2026
3.1 The Global Allergic Rhinitis Drugs Market: Market Overview
3.2 Categorisation Of The Global Allergic Rhinitis Drugs Market
3.3 The Global Allergic Rhinitis Drugs Market in 2015
3.4 The Global Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
3.5 Allergic Rhinitis Drugs: Changing Market Shares by Sector 2016-2026

4. Oral Antihistamines Market: Market Analysis And Forecast 2016-2026
4.1 Oral Antihistamines: Market Overview
4.1.1 Leading Products in the Oral Antihistamines Market, 2015
4.2 Oral Antihistamines: Market Trends and Developments, 2016
4.2.1 Patent Expiries and the Threat of Generics
4.2.2 The Increasing Switch from Prescription to Over-The-Counter Sales
4.2.3 The Potential for Combination Therapy with Intranasal Corticosteroids
4.3 Oral Antihistamines: Market Forecast 2016-2026
4.3.1 Oral Antihistamines: Changing Market Shares by Leading Drugs 2016-2026
4.4 Leading Oral Antihistamines for the Treatment of Allergic Rhinitis
4.4.1 Allegra/Allegra-D/Allegra OTC (fexofenadine) – Sanofi
4.4.1.1 Allegra/Allegra OTC: Historical Sales, 1995-2014
4.4.1.2 Allegra/Allegra OTC: Sales Forecast 2015-2026
4.4.2 Claritin/Claritin OTC (loratadine) – Bayer/ Merck & Co
4.4.2.1 Claritin/Claritin OTC: Sales Forecast 2016-2026
4.4.3 Zyrtec/Zyrtec D (cetirizine) – Johnson & Johnson/ UCB/ GSK
4.4.3.1 Zyrtec/Zyrtec D: Sales Forecast 2016-2026
4.4.5 Xyzal (levocetirizine) – Sanofi/ UCB/ GSK
4.4.5.1 Xyzal: Sales Forecast 2016-2026
4.4.6 Clarinex (desloratadine) – Merck & Co.
4.4.6.1 Clarinex: Sales Forecast 2016-2026
4.4.7 Allelock (olopatadine) – Kyowa Hakko Kirin
4.4.7.1 Allelock: Sales Forecast 2016-2026
4.4.8 Ebastel (ebastine) – AstraZeneca/Takeda/Dainippon Sumitomo
4.4.8.1 Ebastel: Sales Forecast 2016-2026
4.4.9 Talion (bepotastine) – Mitsubishi Tanabe
4.4.9.1 Talion: Sales Forecast 2016-2026
4.4.10 Other Oral Antihistamines: Sales Forecast 2016-2026

5. Intranasal Corticosteroids Market: Market Analysis and Forecast 2016-2026
5.1 Leading Products in the Intranasal Corticosteroids Market, 2015
5.2 Intranasal Corticosteroids: Market Forecast 2016-2026
5.2.1 Intranasal Corticosteroids: Changing Market Shares By Leading Drugs 2016-2026
5.3 Leading Intranasal Corticosteroids
5.3.1 Flixonase/Flonase/Flonase-OTC (fluticasone propionate) – GlaxoSmithKline
5.3.1.1 Flixonase/Flonase/Flonase-OTC Forecast, 2016-2026
5.3.2 Nasonex (mometasone) – Merck
5.3.2.1 Nasonex Forecast, 2016-2026
5.3.3 Avamys/Veramyst (fluticasone furoate) – GlaxoSmithKline
5.3.3.1 Avamys/Veramyst Forecast, 2016-2026
5.3.4 Rhinocort (budesonide) – AstraZeneca
5.3.4.1 Rhinocort Forecast, 2016-2026
5.3.5 Nasacort/Nasacort-OTC (triamcinolone) – Sanofi
5.3.5.1 Nasacort/Nasacort-OTC Forecast, 2016-2026
5.3.6 Omnaris (ciclesonide) – Dainippon Sumitomo/Takeda
5.3.6.1 Omnaris: Sales Forecast, 2016-2026
5.3.7 Beconase/Beconase AQ (beclometasone) – GlaxoSmithKline/Omega Pharma
5.3.7.1 Beconase/Beconase AQ Forecast, 2016-2026
5.3.8 Qnasl (beclometasone) – Teva
5.3.8.1 Qnas Forecast, 2016-2026
5.3.9 Zetonna (ciclesonide) – Dainippon Sumitomo
5.3.9.1 Zetonna Forecast, 2016-2026

6. Immunotherapy and Vaccines: Market Analysis and Forecast 2016-2026
6.1 Immunotherapy and Vaccines: Market Overview
6.1.1 Immunotherapy: Primed for Rapid Expansion
6.2 Leading Immunotherapy Products in the Allergic Rhinitis Market, 2015
6.3 Allergic Rhinitis Immunotherapy: Market Trends and Developments, 2016
6.3.1 Subcutaneous and Sublingual Immunotherapy
6.3.2 Expansion into the US Market
6.3.3 Standardisation of Immunotherapy Products
6.3.4 Immunotherapy as a Preventative Treatment
6.4 Allergic Rhinitis Immunotherapy: Market Forecast 2016-2026
6.4.1 Allergic Rhinitis Immunotherapy: Changing Market Shares by Leading Products 2016-2026
6.5 Immunotherapy Type – By Route of Administration, 2015
6.6 Leading Immunotherapy Products for Allergic Rhinitis
6.6.1 Staloral (Grass pollen allergen extract) – Stallergenes
6.6.1.1 Staloral: Sales Forecast 2016-2026
6.6.2 Alutard SQ (Grass pollen allergen extract) – ALK-Abelló
6.6.2.1 Alutard SQ: Sales Forecast 2016-2026
6.6.3 Grazax/Grastek (Timothy grass pollen allergen extract) – ALK-Abelló/Merck
6.6.3.1 Grazax/Grastek: Sales Forecast 2016-2026
6.6.4 Oralair (Grass pollen allergen extract) – Stallergenes/Greer
6.6.4.1 Oralair: Sales Forecast 2016-2026
6.6.5 Ragwitek (Short ragweed pollen allergen extract) – Merck
6.6.5.1 Ragwitek: Sales Forecast 2016-2026
6.6.6 Other Allergic Rhinitis Immunotherapy Products: Sales Forecast 2016-2026

7. The Intranasal Antihistamines Market: Market Analysis and Forecast 2016-2026
7.1 Leading Products in the Intranasal Antihistamines Market, 2015
7.2 Intranasal Antihistamines: Market Trends and Developments, 2016
7.3 Intranasal Antihistamines: Market Forecast 2016-2026
7.4 Leading Intranasal Antihistamines
7.4.1 Dymista (azelastine/fluticasone) – Meda Pharmaceuticals
7.4.1.1 Mylan Acquires Meda Pharmaceuticals
7.4.1.2 Dymista: Sales Forecast 2016-2026
7.4.2 Generic Intranasal Azelastine
7.4.2.1 Generic Intranasal Azelastine: Sales Forecast, 2016-2026
7.4.3 Astepro (azelastine) – Meda Pharmaceuticals
7.4.3.1 Astepro: Sales Forecast 2016-2026
7.4.4 Patanase (olopatadine) – Novartis
7.4.4.1 Patanase: Sales Forecast 2016-2026
7.4.5 Astelin (azelastine) – Meda Pharmaceuticals
7.4.5.1 Astelin: Sales Forecast 2016-2026

8. Leading National Markets for Allergic Rhinitis Drugs, 2016-2026
8.1 The Allergic Rhinitis Drugs Market by Region
8.1.1 The Global Distribution of Allergic Rhinitis Drugs in 2015
8.2 Leading National Markets: Forecast 2016-2026
8.2.1 Changing Market Shares by Region, 2016-2026
8.3 Regional Allergic Rhinitis Drugs Markets: Analysis and Forecasts, 2016-2026
8.3.1 United States: The Largest Allergic Rhinitis Drugs Market
8.3.1.1 US Allergic Rhinitis Drugs Market: Trends and Developments
8.3.1.1.1 The Trend of Rx-to-OTC Switching
8.3.1.2 US Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
8.3.2 EU5
8.3.2.1 EU5 Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
8.3.2.2 EU5 Markets: Changing Market Shares by Country, 2016-2026
8.3.2.3 Germany
8.3.2.3.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
8.3.2.3.2 German Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
8.3.2.4 UK
8.3.2.4.1 UK: Increasing Burden of Allergy
8.3.2.4.2 UK Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
8.3.2.5 France
8.3.2.5.1 France: Social Security Finance Act 2015
8.3.2.5.2 French Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
8.3.2.6 Italy
8.3.2.6.1 Italy: Government Cost Cutting Measures Impacting Market Growth
8.3.2.6.2 Italian Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
8.3.2.7 Spain
8.3.2.7.1 Spanish Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
8.6 China
8.6.1 Air Pollution Associated With Increasing Prevalence
8.6.2 Expansion of Healthcare Coverage and Reimbursement in China
8.6.3 Chinese Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
8.7 Japan
8.7.1 Cedar Reforestation and the Hay Fever Epidemic
8.7.2 Genetically Modified Rice as Immunotherapy
8.7.3 Effects of the Rising Levels of Generic Drug Penetration
8.7.4 Japanese Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
8.8 Russia
8.8.1 How Will Russia’s Economic Status Affect Its Pharma Industry?
8.8.2 Russian Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
8.9 India
8.9.1 The Impact of the Drug Prices Control Order on Indian Pharma
8.9.2 India’s Expansion of Healthcare Provision
8.9.3 Indian Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
8.10 Brazil
8.10.1 How Will Brazil’s Growing Healthcare Influence Allergic Rhinitis Drugs
8.10.2 Brazilian Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
8.12 Rest of the World
8.12.1 Rest of the World Allergic Rhinitis Drugs Market: Market Forecast 2016-2026

9. Leading Companies in the Allergic Rhinitis Drugs Market, 2016-2026
9.1 Allergic Rhinitis Drugs – An Evolving Market Space
9.1.1 Leading Companies in the Allergic Rhinitis Drugs Market, 2016
9.2 ALK-Abelló
9.2.1 ALK-Abelló: Allergic Rhinitis Drugs Portfolio, 2016
9.2.2 ALK-Abelló: Recent Developments
9.2.2.1 Acarizax Launched in Europe progressing to International Roll-Out
9.2.2.2 ALK Collaborates With EddingPharm to Boost China Sales
9.2.2.3 ALK-Abelló: Sales Forecast 2016-2026
9.2.2.4 ALK-Abelló: Allergic Rhinitis Drug Development Pipeline, 2016
9.3 GlaxoSmithKline (GSK)
9.3.1 GlaxoSmithKline: Allergic Rhinitis Drugs Portfolio, 2016
9.3.2 GlaxoSmithKline: Sales Forecast 2016-2026
9.4 Johnson & Johnson
9.4.1 Johnson & Johnson: Allergic Rhinitis Drugs Portfolio, 2016
9.4.2 Johnson & Johnson: Recent Developments
9.4.2.1 Manufacturing Recalls At McNeil Consumer Healthcare
9.4.2.2 Johnson & Johnson: Sales Forecast 2016-2026
9.5 Kyowa Hakko Kirin
9.5.1 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Portfolio, 2015
9.5.2 Kyowa Hakko Kirin: Sales Forecast 2016-2026
9.6 Merck & Co.
9.6.1 Merck: Allergic Rhinitis Drugs Portfolio, 2016
9.6.2 Merck: Recent Developments
9.6.2.1 Bayer Acquires Merck’s Consumer Health Business
9.6.2.2 FDA Rejects Singulair OTC Switch
9.2.6.3 Merck: Sales Forecast 2016-2026
9.2.6.4 Merck: Allergic Rhinitis Drug Development Pipeline, 2016
9.7 Sanofi
9.7.1 Sanofi: Allergic Rhinitis Drugs Portfolio, 2016
9.7.2 Sanofi: Sales Forecast 2016-2026
9.8 Stallergenes Greer
9.8.1 Stallergenes: Allergic Rhinitis Drugs portfolio, 2015
9.8.2 Stallergenes Greer: Sales Forecast 2016-2026
9.8.3 Stallergenes Greer: Allergic Rhinitis Drug Development Pipeline, 2015
9.9 UCB
9.9.1 UCB: Allergic Rhinitis Drugs Portfolio, 2015
9.9.2 UCB: Sales Forecast 2016-2026
9.10 Other Leading Companies within the Allergic Rhinitis Drugs Market

10. Allergic Rhinitis Drugs: Research and Development Pipeline, 2016-2026
10.1 Trends and Developments in the Allergic Rhinitis Pipeline
10.2 The R&D Pipeline for Oral Antihistamines, 2016
10.2.1 Talion (bepotastine) – Mitsubishi Tanabe
10.2.2 ZPL-3893787 (histamine H4R antagonist) – Ziarco Pharma
10.3 The R&D Pipeline for Intranasal Corticosteroids, 2016
10.3.1 APC-3000 (HFA inhaled corticosteroid) – Adamis Pharmaceuticals
10.3.2 TBS-6 – Trimel Pharmaceuticals
10.4 The R&D Pipeline for Immunotherapy in Allergic Rhinitis, 2016
10.4.1 Actair (house dust mite SLIT; STG320) – Stallergenes/Shionogi & Co
10.4.2 AllerT (subcutaneous birch pollen immunotherapy) – Anergis
10.4.3 Depigoid Birch 5000 (birch pollen allergen extract, Leti Pharma
10.4.4 House Dust Mite SLIT-Tablet (MK-8237) – ALK-Abelló/Merck/Torii
10.4.5 Pollinex Quattro (subcutaneous immunotherapies) – Allergy Therapeutics
10.4.6 gp-ASIT+ (grass pollen allergen fragments) – Biotech Tools
10.4.7 Betula verrucosa (Bet v) 1 allergen – Stallergenes Greer
10.5 The R&D Pipeline for Other Allergic Rhinitis Drugs
10.5.1 S-555739 (prostaglandin D2 receptor antagonist) – Shionogi
10.5.2 DSP-3025/AZD-8848 (toll-like receptor 7 agonist) – Dainippon Sumitomo/ AstraZeneca
10.5.3 GSK2245035 (toll-like receptor 7 agonist) – GSK
10.5.4 HP-3060 (transdermal long-acting tape) – Hisamitsu
10.5.5 MRX-4 (anti-inflammatory agent) – Celsus Therapeutics

11. Qualitative Analysis of the Allergic Rhinitis Drugs Market, 2016-2026
11.1 Market Factors Influencing Allergic Rhinitis Drugs
11.2 SWOT Analysis Of The Global Allergic Rhinitis Drugs Market, 2016-2026
11.2.1 Strengths
11.2.1.1 OTC-Switch Facilitating Ease Of Consumer Access
11.2.1.2 The Established Role Of Allergic Rhinitis Drugs In Treatment
11.2.1.3 Allergic Rhinitis And The Rising Unmet Clinical Need
11.2.1.4 Rising Profile of Allergic Rhinitis In Various Regions Driving Healthcare Provision
11.2.2 Weaknesses
11.2.2.1 Intranasal Corticosteroids And Patients’ Satisfaction Rates
11.2.2.2 Increasing Penetration Of Generic Drug Products
11.2.2.3 The Challenge Raised By The Low Volume Of Pipeline Developments
11.2.3 Opportunities
11.2.3.1 Growth In Emerging Markets Outstripping Established Markets
11.2.3.2 Rx-to-OTC Switching And The Effects On Revenue Potential
11.2.3.3 Combination Drug Products Providing Rising Efficacy Profiles
11.2.3.4 The Emergence Of Immunotherapy In Allergic Rhinitis
11.2.4 Threats
11.2.4.1 Cost-Containment As A Growth Restraint
11.2.4.2 Rising Cost Of APIs And Manufacturing
11.2.4.3 Patent Expiries And The Resultant Loss Of Revenue
11.3 Porter’s Five Force Analysis of the Global Allergic Rhinitis Drugs Market, 2016-2026
11.3.1 Power of Buyers
11.3.2 Power Of Suppliers
11.3.3 Threat of Substitutes
11.3.4 Threat Of New Entrants
11.3.5 Rivalry Among Competitors

12. Conclusions
12.1 Overview of Current Market Conditions and Market Forecast, 2015-2026
12.2 Leading Sectors in the Allergic Rhinitis Drugs Market in 2015
12.3 Leading Regions in the Allergic Rhinitis Drugs Market in 2015
12.4 Leading Companies in the Allergic Rhinitis Drugs Market, 2015
12.5 What Does The Future Hold For Allergic Rhinitis Drugs?

List of Tables
Table 1.1 Allergic Rhinitis Market Forecast by National Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 2.1 Leading Antihistamines for Allergic Rhinitis, 2015
Table 2.2 Leading Corticosteroids for Allergic Rhinitis, 2016
Table 2.3 Clinical Trial Phases
Table 3.1 The Global Allergic Rhinitis Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2015
Table 3.2 The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
Table 3.4 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2015, 2020, 2026
Table 4.1 Leading Oral Antihistamines: Revenue ($m) and Market Share (%), 2015
Table 4.2 Oral Antihistamines Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
Table 4.3 The Global Oral Antihistamines Market: Market Share (%), 2015, 2020, 2026
Table 4.4 Allegra/Allegra-D/Allegra OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 4.5 Claritin/Claritin OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 4.6 Zyrtec/Zyrtec-D Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 4.7 Xyzal Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
Table 4.8 Clarinex Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
Table 4.9 Allelock Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 4.10 Ebastel Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 4.11 Talion Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 4.12 Other Oral Antihistamines Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
Table 5.1 Leading Drugs In The Intranasal Corticosteroids Market: Revenue ($m) and Market Shares (%), 2015
Table 5.2 Intranasal Corticosteroids Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2026
Table 5.3 The Global Intranasal Corticosteroids Market: Market Share (%), 2015, 2020, 2026
Table 5.4 Flixonase/Flonase/Flonase-OTC Forecast: Revenue ($m), AGR (%), and CAGR (%), 2015-2026
Table 5.5 Nasonex Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 5.6 Avamys/Veramyst Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 5.7 Rhinocort: Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 5.8 Nasacort/Nasacort-OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 5.9 Omnaris Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 5.10 Beconase/Beconase AQ Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 5.11 Qnasl Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 5.12 Zetonna Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 6.1 Leading Allergic Rhinitis Immunotherapy Products: Revenue ($m) and Market Share (%), 2015
Table 6.2 Allergic Rhinitis Immunotherapy Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
Table 6.3 The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2015, 2020, 2026
Table 6.4 Allergic Rhinitis Immunotherapy Market by Type: Revenue ($m) and Market Share (%), 2015
Table 6.5 Staloral Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 6.6 Alutard SQ Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
Table 6.7 Grazax/Grastek Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
Table 6.8 Oralair Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 6.9 Ragwitek Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 6.10 Other Allergic Rhinitis Immunotherapy Products Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 7.1 Top Drugs In The Intranasal Antihistamines Market: Revenue ($m) and Market Shares (%), 2015
Table 7.2 Intranasal Antihistamines Market Forecast by Leading Drugs: Revenue ($m), AGR (%), and CAGR%), 2015-2026
Table 7.3 The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2015, 2020, 2026
Table 7.4 Dymista (Meda Pharma) Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 7.5 Generic Intranasal Azelastine Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 7.6 Astepro Forecast; Revenue ($m), AGR (%) and CAGR (%), 2015-2025
Table 7.7 Patanase Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 7.8 Astelin Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 8.1 The Global Allergic Rhinitis Drugs Market by Region: Revenue ($m) and Market Share (%), 2015
Table 8.2 Global Allergic Rhinitis Drugs Market Forecast by Region: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 8.3 The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2015, 2020, and 2026
Table 8.4 US Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 8.5 The EU5 Allergic Rhinitis Drugs Market Forecast by Country: Revenue ($m) and Market Share (%), 2015
Table 8.6 The EU5 Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
Table 8.7 The EU5 Allergic Rhinitis Drugs Market by Country: Market Share (%), 2015, 2020, 2026
Table 8.8 German Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 8.9 UK Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 8.10 French Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2015-2026
Table 8.11 Italian Allergic Rhinitis Drugs Market Forecat: Revenue ($m), AGR (%), and CAGR (%), 2015-2026
Table 8.12 Spanish Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2015-2026
Table 8.13 Chinese Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
Table 8.14 Japanese Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2015-2026
Table 8.15 Russian Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 8.16 Indian Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 8.17 Brazilian Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 8.18 Rest of the World Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
Table 9.1 Leading Companies In The Allergic Rhinitis Drug Market: Revenues ($m) and Market Shares (%), 2015
Table 9.2 ALK- Abelló: Company Overview, 2016
Table 9.3 ALK-Abelló: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 9.4 GlaxoSmithKline: Company Overview, 2016
Table 9.5 GlaxoSmithKline: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 9.6 Johnson & Johnson: Company Overview, 2016
Table 9.7 Johnson & Johnson Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 9.8 Kyowa Hakko Kirin: Company Overview, 2016
Table 9.9 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 9.10 Merck & Co: Company Overview, 2016
Table 9.11 Merck & Co: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
Table 9.12 Sanofi: Company Overview, 2016
Table 9.13 Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
Table 9.14 Stallergenes Greer: Company Overview, 2015
Table 9.15 Stallergenes Greer: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
Table 9.16 UCB: Company Overview, 2016
Table 9.17 UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
Table 11.1 SWOT Analysis of the Global Allergic Rhinitis Drugs Market, 2016-2026

List of Figures
Figure 1.1 Global Allergic Rhinitis Drugs Market: Market Sectors, 2015
Figure 2.1 Role of Mast Cells and IgE in Allergic Rhinitis, 2016
Figure 3.1 The Global Allergic Rhinitis Drugs Market: Revenue ($m) by Sector, 2015
Figure 3.2 The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%) by Sector, 2015-2026
Figure 3.3 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2015
Figure 3.4 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2020
Figure 3.5 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2026
Figure 4.1 Leading Oral Antihistamines: Revenue ($m), 2015
Figure 4.2 Oral Antihistamines Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 4.3 The Global Oral Antihistamines Market: Market Share(%), 2015
Figure 4.4 The Global Oral Antihistamines Market: Market Share (%), 2020
Figure 4.5 The Global Oral Antihistamines Market: Market Share (%), 2026
Figure 4.6 Allegra (Allegra Rx and Allegra OTC) Historical Sales: Revenue ($m),1995-2015
Figure 4.7 Allegra/Allegra-D/Allegra OTC Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 4.8 Claritin/Claritin OTC Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 4.9 Zyrtec/Zyrtec-D Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 4.10 Xyzal Forecast: Revenue($m) and AGR (%), 2015-2026
Figure 4.11 Clarinex Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 4.12 Allelock Forecast: Revenue($m) and AGR (%), 2015-2026
Figure 4.13 Ebastel Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 4.14 Talion Forecast: Revenue($m) and AGR (%), 2015-2026
Figure 4.15 Other Oral Antihistamines Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 5.1 Leading Drugs In The Intranasal Corticosteroids Market: Revenue ($m), 2014
Figure 5.2 Intranasal Corticosteroids Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 5.3 The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2015
Figure 5.4 The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2020
Figure 5.5 The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2026
Figure 5.6 Flixonase/Flonase/Flonase-OTC Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 5.7 Nasonex Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 5.8 Avamys/Veramyst Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 5.9 Rhinocort Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 5.10 Nasacort/Nasacort-OTC Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 5.11 Omnaris Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 5.12 Beconase/Beconase AQ Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 5.13 Qnasl Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 5.14 Zetonna Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 6.1 Leading Allergic Rhinitis Immunotherapy Products: Revenue ($m), 2015
Figure 6.2 Allergic Rhinitis Immunotherapy Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 6.3 The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2015
Figure 6.4 The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2020
Figure 6.5 The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2026
Figure 6.6 Allergic Rhinitis Immunotherapy Market: Market Share (%) by Immunotherapy Type, 2015
Figure 6.7 Staloral Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 6.8 Alutard SQ Forecast: Revenue($m) and AGR (%), 2015-2026
Figure 6.9 Grazax/Grastek Forecast: Revenue($m) and AGR (%), 2015-2026
Figure 6.10 Oralair Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 6.11 Ragwitek Forecast: Revenue ($m) and AGR (%), 201-2026
Figure 6.12 Other Allergic Rhinitis Immunotherapy Products Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 7.1 Top Drugs In The Intranasal Antihistamines Market: Revenue ($m), 2015
Figure 7.2 Intranasal Antihistamines Market Forecast: Revenue ($m), AGR (%), 2015-2026
Figure 7.3 The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2015
Figure 7.4 The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2020
Figure 7.5 The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%, 2026
Figure 7.6 Dymista (Meda Pharma) Forecast: Revenue ($m) and AGR(%), 2015-2026
Figure 7.7 Generic Intranasal Azelastine Forecast: Revenue ($m) and, AGR (%), 2015-2026
Figure 7.8 Astepro Forecast: Revenue ($m), and AGR (%), 2015-2026
Figure 7.9 Patanase Forecast: Revenue($m) and AGR (%), 2015-2026
Figure 7.10 Astelin Forecast: Revenue ($m), AGR (%), 2015-2026
Figure 8.1 The Global Allergic Rhinitis Drugs Market By Region: Revenue ($m), 2015
Figure 8.2 The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2015
Figure 8.3 The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2020
Figure 8.4 The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2026
Figure 8.5 US Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 8.6 The EU5 Allergic Rhinitis Drugs Market by Country: Revenue ($m), 2015
Figure 8.7 The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2015
Figure 8.8 The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2020
Figure 8.9 The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2026
Figure 8.10 German Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 8.11 UK Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 8.12 French Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 8.13 Italian Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 8.14 Spanish Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 8.15 Chinese Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 8.16 Japanese Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 8.17 Russian Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 8.18 Indian Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 8.19 Brazilian Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 8.20 Rest of the World Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 9.1 Leading Companies In The Allergic Rhinitis Drug Market: Revenues ($m), 2015
Figure 9.2 ALK-Abelló: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%), 2015-2026
Figure 9.3 GlaxoSmithKline Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 9.4 Johnson & Johnson Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 9.5 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 9.6 Merck & Co: Allergic Rhinitis Drugs Revenue Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 9.7 Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.8 Stallergenes Greer: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2015-2026
Figure 9.9 UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2015-2026
Figure 11.1 Porter’s Five Force Analysis of the Allergic Rhinitis Drugs Market, 2016

★調査レポート[アレルギー性鼻炎治療薬の世界市場予測2016-2026] ( Allergic Rhinitis Drugs Market Forecast 2016-2026 / VGAIN61118) 販売に関する免責事項
[アレルギー性鼻炎治療薬の世界市場予測2016-2026] ( Allergic Rhinitis Drugs Market Forecast 2016-2026 / VGAIN61118) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆